Q-Line Biotech IPO Ki Dhamakedar Shuruaat, Bio Medica Labs IPO Sukha! Kya Hai Pura Scene?

IPO
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Q-Line Biotech IPO Ki Dhamakedar Shuruaat, Bio Medica Labs IPO Sukha! Kya Hai Pura Scene?
Overview

Bhai log, Q-Line Biotech ka IPO toh opening day par hi **3.82x** subscribe ho gaya, matlab demand bhaari thi! Lekin Bio Medica Laboratories ka IPO ekdum down chal raha hai, abhi tak undersubscribed hai. Dono IPO **25th May** tak khule hain, toh dekhna padega aage kya hota hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Q-Line Biotech ne toh pehle hi din IPO market mein aag laga di! Investors ka pyaar itna mila ki opening day par hi 3.82 times subscribe ho gaya. Company ₹214.5 crore raise karna chahti hai aur ek share ka price ₹326 se ₹343 ke beech hai. Maza toh yeh hai ki anchor investors se toh ₹61.09 crore pehle hi mil chuke hain. Paisa use hoga working capital ke liye, loan chukane ke liye aur general company kaam ke liye.

FY25 mein Q-Line Biotech ne ₹313.78 crore ka revenue aur ₹28.13 crore ka profit kamaya hai. Lagta hai company diagnostic market ke growth ka poora fayda utha rahi hai.

Doosri taraf, Bio Medica Laboratories ka IPO market mein theek se perform nahi kar paya. Pehle din 68% hi subscribe hua hai, matlab investors utna excited nahi hain. Company ₹52.4 crore raise karna chahti hai aur share price ₹132 se ₹139 ke beech hai.

Qualified Institutional Buyers ne toh interest dikhaya hai, par baaki investors abhi soch rahe hain. Paisa loan chukane aur naya manufacturing facility banane mein lagega. FY25 mein revenue ₹38.20 crore aur profit ₹9.8 crore tha, par negative operating cash flow aur badhta hua debt investors ko pareshan kar raha hai.

Market ka view bhi alag-alag hai. Q-Line Biotech ki success healthcare spending aur early disease detection par focus ki wajah se hai. Unke numbers aur anchor investors ka support confidence badha raha hai. Bio Medica Laboratories generic contract manufacturing mein hai jahan competition bahut zyada hai aur profit kam milta hai. Unka badhta hua debt aur negative cash flow sabse badi chinta ka vishay hai.

Bio Medica Laboratories ke liye badhta hua debt aur negative operating cash flow ek warning sign ho sakta hai. Unki 75.11% revenue sirf top 10 clients se aati hai, jo ek risk hai. Pharmaceutical contract manufacturing sector mein strict rules aur competition profit margins ko daba dete hain. Q-Line Biotech ko bhi apna profit maintain karna hoga aur working capital manage karna hoga, khaas kar jab unka Debt/Equity ratio 1.06 hai.

Yaad rakho, dono IPO 25th May tak khule hain. Q-Line Biotech ka start zabardast hai, aur Bio Medica Laboratories ko apne financial issues aur competition ko tackle karna hoga.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.